ChiCTR2500096644 版本V1.0 版本创建时间2025/01/27 14:52:50 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500096644 

最近更新日期:

Date of Last Refreshed on:

2025-01-27 14:52:32 

注册时间:

Date of Registration:

2025-01-27 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

乳腺癌术后患者上肢淋巴水肿全程管理干预模式的研究

Public title:

Study on intervention mode of upper limb lymphedema management after breast cancer surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

乳腺癌术后患者上肢淋巴水肿全程管理干预模式的研究

Scientific title:

Study on intervention mode of upper limb lymphedema management after breast cancer surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘艳飞 

研究负责人:

刘均娥 

Applicant:

Yanfei Liu 

Study leader:

Liu Jun’e  

申请注册联系人电话:

Applicant telephone:

+86 188 1082 9490

研究负责人电话:

Study leader's
telephone:

+86 185 0013 6128

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

851122725@qq.com

研究负责人电子邮件:

Study leader's E-mail:

liujune66@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河南省郑州市高新区科学大道101号

研究负责人通讯地址:

北京市丰台区右安门外西头条10号首都医科大学

Applicant address:

No.101 Science Avenue, High-tech Zone, Zhengzhou, Henan

Study leader's address:

Capital Medical University, No. 10, Xitou Tiao, You'anmen Outer, Fengtai District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

郑州大学护理与健康学院

Applicant's institution:

School of Nursing and Health, Zhengzhou University

研究负责人所在单位:

首都医科大学

Affiliation of the Leader:

Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

Z2019SY022

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2019-04-23 00:00:00

伦理委员会联系人:

刘芳

Contact Name of the ethic committee:

Liu Fang

伦理委员会联系地址:

北京市丰台区右安门外西头条10号首都医科大学

Contact Address of the ethic committee:

Capital Medical University, No. 10, Xitou Tiao, You'anmen Outer, Fengtai District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8391 1736

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学

Primary sponsor:

Capital Medical University

研究实施负责(组长)单位地址:

北京市丰台区右安门外西头条10号

Primary sponsor's address:

No. 10, Xitou Tiao, You'anmen Outer, Fengtai District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学

具体地址:

北京市丰台区右安门外西头条10号

Institution
hospital:

Capital Medical University

Address:

No. 10, Xitou Tiao, You'anmen Outer, Fengtai District, Beijing, China

经费或物资来源:

北京市自然科学基金

Source(s) of funding:

Beijing Natural Science Foundation

研究疾病:

乳腺癌淋巴水肿  

Target disease:

Breast cancer lymphedema

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

评价运动干预对乳腺癌淋巴水肿,健康体适能,心理状况和生活质量的影响等。  

Objectives of Study:

To evaluate the effects of exercise intervention on lymphedema, physical fitness, psychological status and quality of life of breast cancer.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①病理诊断确诊为乳腺癌; ②乳腺癌术后,含根治术、改良根治术、保乳术;行腋窝淋巴结清扫或前哨淋巴结摘除术后; ③术后6个月以上的康复者; ④知情同意、自愿参与本次研究; ⑤年龄18~70岁。

Inclusion criteria

1. Pathological diagnosis of breast cancer; 2. Postoperative breast cancer, including radical surgery, modified radical surgery, breast conservation surgery; After axillary lymph node dissection or sentinel lymph node extraction; 3. Patients recovered more than 6 months after surgery; 4. Informed consent and voluntary participation in the study; 5. Age 18 ~ 70 years old.

排除标准:

①已复发或转移; ②合并有其它癌症; ③既往患有精神病史及意识障碍; ④患侧上肢有骨折、手术、神经损伤或其他疾病而影响锻炼; ⑤合并其他严重疾病(如严重高血压、心脏病等)不能配合本研究; ⑥既往有精神疾病。

Exclusion criteria:

1. Has recurred or metastasized; 2. Combined with other cancers; 3. Have a history of mental illness and consciousness disorder; 4. There are fractures, surgery, nerve damage or other diseases on the affected side of the upper limb that affect exercise; 5. Combined with other serious diseases (such as severe hypertension, heart disease, etc.) can not cooperate with this study; 6. Previous mental illness.

研究实施时间:

Study execute time:

From 2019-09-10 00:00:00 To 2020-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-09-28 00:00:00 To 2020-01-03 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

43

Group:

intervention group

Sample size:

干预措施:

为期12周的乳腺癌康复者预防上肢淋巴水肿运动处方干预方案。

干预措施代码:

Intervention:

The 12-week exercise prescription intervention program for preventing upper limb lymphedema for breast cancer survivors.

Intervention code:

组别:

对照组

样本量:

43

Group:

control group

Sample size:

干预措施:

实施常规健康教育团体干预和出院随访,包括淋巴水肿监测和居家运动指导。

干预措施代码:

Intervention:

Routine health education group intervention and discharge follow-up were carried out, including lymphedema monitoring and home exercise guidance.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京世纪坛医院 

单位级别:

三甲 

Institution
hospital:

Beijing Millennium Temple Hospital affiliated to Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

淋巴水肿严重程度

指标类型:

主要指标

Outcome:

Lymphedema severity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

上肢臂围差

指标类型:

主要指标

Outcome:

Arm Muscle Circumference,AMC

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

医院焦虑抑郁量表

指标类型:

次要指标

Outcome:

The Hospital Anxiety and Depression Scale,HADS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

国际体力活动水平问卷

指标类型:

主要指标

Outcome:

International Physical Activity Questionnaire, IPAQ

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

慢性病治疗功能评估-疲劳量表问卷

指标类型:

次要指标

Outcome:

Functional Assessment of Chronic Illness Therapy-Fatigue,FACIT-F

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简易体能状态评定

指标类型:

次要指标

Outcome:

Short Physical Performance Battery,SPPB

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后,ResMan, http://www.medresman.org.cn/login.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the study, ResMan, http://www.medresman.org.cn/login.aspxo

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究运用 Epi Data3.1双人录入进行数据统计,运用IBM SPSS Statistics 24.0统计软件进行数据分析

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

In this study, Epi Data 3.1 was used for data statistics and IBM SPSS Statistics 24.0 statistical software was used for data analysis

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-01-27 14:52:32